or Try an Advanced Search...

    Technical Analysis for CRVO - CervoMed Inc.

    Grade Last Price % Change Price Change
    B 23.82 -4.68% -1.17
    CRVO closed down 4.68 percent on Friday, April 26, 2024, on approximately normal volume.
    Earnings due: May 13
    *** please verify all earnings dates ***
    0 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Up Up Down
    Historical CRVO trend table...
    Date Alert Name Type % Chg
    Outside Day Range Expansion 0.00%
    Gapped Down Weakness 0.00%
    Narrow Range Bar Range Contraction -4.68%
    Inside Day Range Contraction -4.68%
    Up 3 Days in a Row Strength -4.68%
    Doji - Bearish? Reversal -3.17%
    Outside Day Range Expansion -3.17%
    Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -1.93%
    NR7 Range Contraction -1.93%
    Narrow Range Bar Range Contraction -1.93%
    Older End-of-Day Signals for CRVO ...

       Recent Intraday Alerts

    Alert Time
    Up 2% about 18 hours ago
    Possible NR7 about 18 hours ago
    Down 1% about 20 hours ago
    Up 1% about 20 hours ago
    Rose Above Previous Day's High about 21 hours ago
    View Earlier Intraday Alerts

    Get this analysis on your stocks daily!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Read My Charts!
    Configure default chart indicators
    CRVO Chart by TradingView
    Basic chart:

    Profile

    CervoMed Inc. is a clinical-stage biotechnology company advancing CNS-focused therapeutics to benefit patients with a range of degenerative diseases of the brain. The Company is currently developing neflamapimod, an investigational orally administered small molecule brain penetrant that inhibits p38MAP kinase alpha (p38a). Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause disease in dementia with Lewy bodies (DLB) and certain other major neurological disorders. Neflamapimod is currently being evaluated in a Phase 2b study in patients with DLB.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Biotechnology Cancer Clinical Development Cancer Treatment Oncology Chemotherapy Radiation Ophthalmology Dermatology Oxygen Blastoma Macular Degeneration Glioblastoma Radiation Therapy Cancer Cell Signal Transduction Acne Brain Tumor mTOR Glioblastoma Multiforme Oncology Applications Acne Vulgaris Pi3k/Akt/Mtor Pathway

    Is CRVO a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Apr 2 Presenting on the Emerging Growth Conference 69 Day 1 on April 3 Register Now
    Apr 2 CervoMed: H2 2024 Data For DLB Program A Major Inflection Point
    Apr 1 CervoMed GAAP EPS of -$0.82 beats by $1.23, revenue of $7.14M beats by $3.09M
    Apr 1 CervoMed Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates
    Mar 5 CervoMed Announces Presentation of Biomarker Data from the AscenD-LB Phase 2a Trial and Preclinical Data Supporting Potential of Neflamapimod in Tau-Mediated Disease at AD/PD ™ 2024
    Feb 21 CervoMed to Participate in the BIO CEO and Investor Conference
    Feb 20 CervoMed appoints drug development veteran Dr. Joshua Boger as Chairman of the Board
    Feb 12 CervoMed Publishes Positive Results from AscenD-LB Phase 2a Trial in Peer-Reviewed Journal that Supports the Therapeutic Potential of Neflamapimod in Dementia with Lewy Bodies
    Feb 5 CervoMed to Participate in the Emerging Growth Conference 67
    Jan 5 CervoMed to Participate in the Emerging Growth Conference 66
    See more CRVO news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 26.3789
    52 Week Low 4.14
    Average Volume 33,102
    200-Day Moving Average 10.58
    50-Day Moving Average 19.84
    20-Day Moving Average 23.66
    10-Day Moving Average 24.40
    Average True Range 2.09
    RSI (14) 54.95
    ADX 18.52
    +DI 17.82
    -DI 15.31
    Chandelier Exit (Long, 3 ATRs) 19.65
    Chandelier Exit (Short, 3 ATRs) 22.47
    Upper Bollinger Bands 26.46
    Lower Bollinger Band 20.87
    Percent B (%b) 0.53
    BandWidth 23.63
    MACD Line 1.33
    MACD Signal Line 1.61
    MACD Histogram -0.288
    Fundamentals Value
    Market Cap 135.17 Million
    Num Shares 5.67 Million
    EPS -5.59
    Price-to-Earnings (P/E) Ratio -4.26
    Price-to-Sales 11.27
    Price-to-Book 5.48
    Dividend 0.00
    Dividend Yield 0.00%
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 26.34
    Resistance 3 (R3) 26.62 26.06 25.92
    Resistance 2 (R2) 26.06 25.42 25.92 25.78
    Resistance 1 (R1) 24.94 25.02 24.66 24.66 25.64
    Pivot Point 24.38 24.38 24.24 24.24 24.38
    Support 1 (S1) 23.26 23.74 22.98 22.98 22.00
    Support 2 (S2) 22.70 23.34 22.56 21.86
    Support 3 (S3) 21.58 22.70 21.72
    Support 4 (S4) 21.30